Company / Free Cash Flow
Pacira BioSciences, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$136.7M
FY2025
5-year range
$60.4M / $178.8M
FY2021-FY2025
Trend
-23.5%
vs FY2024
Sector context
#41 of 194
Health Care
What the data says
Pacira BioSciences, Inc.'s free cash flow of $137M is higher than 79% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$12M in FY2017 to $179M in FY2024.
Based on SEC 10-K filings.
$137M in FY2025 with a 5-year CAGR of +31.8%. Top quartile in the Health Care sector.
Declined from $139M to $137M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +5.9%
- 5-Year CAGR
- +31.8%
- 10-Year CAGR
- -
Sector benchmark
-71.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.8%, indicating consistent growth.
- In FY2025, free cash flow decreased 23.5% year-over-year.
- Ranks #41 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.7M | -23.5% |
| FY2024 | $178.8M | +28.1% |
| FY2023 | $139.5M | +21.1% |
| FY2022 | $115.2M | +90.8% |
| FY2021 | $60.4M | +75.7% |
| FY2020 | $34.4M | +2419.8% |
| FY2019 | -$1.5M | -116.9% |
| FY2018 | $8.7M | +171.2% |
| FY2017 | -$12.3M | -240.4% |
| FY2016 | $8.7M | +171.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026